Patrys Limited (ASX:PAB)

3.7¢

right-arrow Created with Sketch. -0.002 (-5.13%)
MCAP $70.46M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

23/11/2021PABPatrys Limited
586
MCap
19/11/2021PABPatrys Limited
10,400
MCap
18/11/2021PABPatrys Limited
294
MCap
18/11/2021PABPatrys Limited
203
MCap
11/11/2021PABPatrys Limited
22,339
MCap
09/11/2021PABPatrys Limited
329
MCap
09/11/2021PABPatrys Limited
439
MCap
09/11/2021PABPatrys Limited
8,303
MCap

Company Overview

Patrys Limited is an Australia-based company, which is engaged in the development of antibody therapies for the treatment of cancer. The Company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The Company is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.

PAB in the news

Patrys (ASX:PAB) eyes $7.8m for PAT-DX3

Patrys (PAB) will be undertaking a $7.8 million capital raising, consisting of…

Patrys (ASX:PAB) shows antibody significantly increases survival

Patrys (PAB) has shown its antibody can be used as a targeting…

Patrys (ASX:PAB) shows deoxymab potential in antibody drug conjugates

Patrys (PAB) shows the potential of its deoxymab antibodies as targeting agents…

Patrys’ (ASX:PAB) clinical trials pushed back

Patrys (PAB) postpones its planned PAT-DX1 clinical trial for up to six…

Search Previous Announcements